PRESS RELEASE published on 06/02/2026 at 07:30, 4 months 1 day ago Inventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris Inventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris en raison d'un projet d'opération de financement. Les négociations devraient reprendre le 2 juin 2026 Euronext Paris Financement Inventiva NATiV3 Suspension Temporaire
BRIEF published on 05/26/2026 at 22:05, 4 months 8 days ago Inventiva Annonce ses Résultats Financiers du Premier Trimestre 2026 Résultats Financiers Biopharmaceutique Trésorerie Inventiva NATiV3
BRIEF published on 05/26/2026 at 22:05, 4 months 8 days ago Inventiva Announces its First Quarter 2026 Financial Results Financial Results Treasury Biopharmaceutical Inventiva NATiV3
PRESS RELEASE published on 05/26/2026 at 22:00, 4 months 8 days ago Inventiva publie ses informations financières du premier trimestre 2026¹ Inventiva publie ses informations financières du premier trimestre 2026, montrant une trésorerie de 75 millions d'euros et des dépôts à court terme de 121,5 millions d'euros Trésorerie Inventiva Trimestre 2026 Dépôts À Court Terme Équivalents De Trésorerie
PRESS RELEASE published on 05/26/2026 at 22:00, 4 months 8 days ago Inventiva Reports 2026 First Quarter Financial Information¹ Inventiva reports first quarter 2026 financial information, with cash and cash equivalents at €75.0 million and short-term deposits at €121.5 million. Explore company's financial results and upcoming milestones Financial Information Inventiva NATiV3 Cash Equivalents Short-term Deposits
BRIEF published on 05/21/2026 at 22:05, 4 months 13 days ago Inventiva to Present at 2026 Jefferies Global Healthcare Conference Biopharmaceutical Inventiva Lanifibranor MASH Treatment Jefferies Conference
BRIEF published on 05/21/2026 at 22:05, 4 months 13 days ago Inventiva à la 2026 Jefferies Global Healthcare Conference Biopharmaceutique Inventiva Conférence Jefferies MASH Lanifibranor
BRIEF published on 05/21/2026 at 22:05, 4 months 13 days ago Inventiva at the 2026 Jefferies Global Healthcare Conference Biopharmaceutical Inventiva MASH Lanifibranor Jefferies Conference
BRIEF published on 05/21/2026 at 22:05, 4 months 13 days ago Inventiva présentera ses travaux lors de la conférence mondiale Jefferies sur les soins de santé 2026. Biopharmaceutique Inventive Conférence Jefferies Lanifibranor Traitement MASH
PRESS RELEASE published on 05/21/2026 at 22:00, 4 months 13 days ago Inventiva présentera lors de la 2026 Jefferies Global Healthcare Conference Inventiva présentera lors de la 2026 Jefferies Global Healthcare Conference à New York City son traitement oral pour la stéatohépatite. Détails de la présentation le 3 juin 2026 Inventiva Lanifibranor Stéatohépatite 2026 Jefferies Global Healthcare Conference Traitement Oral
Published on 10/02/2026 at 13:50, 1 day 16 hours ago AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
Published on 10/02/2026 at 13:00, 1 day 16 hours ago Evergold Drills 4.9 m of 7.70 g/t Au and 186.0 g/t Ag Within 13.5 Metres of 2.84 g/t Au and 127.6 g/t Ag in First 2026 Drill Holes at Golden Lion
Published on 10/02/2026 at 13:00, 1 day 16 hours ago Alaska Energy Metals Appoints Independent Director, Thomas Benson
Published on 10/04/2026 at 05:15, 42 minutes ago SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026
Published on 10/03/2026 at 15:45, 14 hours 12 minutes ago Huawei Highlights Continuous Innovation, Securing Competitive Edge Through Technological Breakthroughs
Published on 10/02/2026 at 23:55, 1 day 6 hours ago IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY
Published on 10/02/2026 at 20:23, 1 day 9 hours ago EQS-Adhoc: Pentixapharm Holding AG: Bafin concludes financial reporting review of the 2024 consolidated financial statements with an error finding
Published on 10/02/2026 at 19:46, 1 day 10 hours ago innoscripta SE: Update on the Tax Authorities’ Investigation – Business Operations Continue as Usual – Full Transparency Assured – Invitation to Shareholders for an In-Person Product Presentation
Published on 10/02/2026 at 17:45, 1 day 12 hours ago Information concerning the total number of voting rights and shares 2026 09 30
Published on 10/02/2026 at 17:45, 1 day 12 hours ago Informations relatives au nombre total de droits de vote et d’actions 2026 09 30
Published on 10/02/2026 at 17:35, 1 day 12 hours ago Peugeot Invest - Déclaration du nombre d'actions et de droits de vote
Published on 10/02/2026 at 17:30, 1 day 12 hours ago Aéroports de Paris SA - Calendrier financier 2027
